Phase 2
N=17
Oral Cyclosporine in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Bottom Line
View on ClinicalTrials.gov: NCT00974142 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
May 2018
Primary outcome: Primary: Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients- Nephrotoxicity - Measured by Serum Creatinine — 0.94; 0.88 mg / dL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Cyclosporine (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- All
- Sponsor
- Michael Donahoe
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients- Nephrotoxicity - Measured by Serum Creatinine |
0.94; 0.88 | — |
| PRIMARY Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients - Number of Patients That Developed Renal Insufficiency |
4; 1 | — |
| PRIMARY Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients - Number of Patients That Developed Infection Requiring Systemic Antibiotic Therapy |
1; 1 | — |
| SECONDARY Pharmacokinetic - Pharmacodynamic Relationship of Oral Cyclosporine and Biomarkers of an Adaptive Immune Response - Cyclosporine Blood Levels |
147 | — |
| SECONDARY Peripheral Blood T Cell Biomarkers Over 16 Week Treatment Interval - Change in the Percentage of Cluster of Differentiation 4 (CD4) |
-3.1; 3.6 | — |
| SECONDARY Peripheral Blood T Cell Biomarkers Over 16 Week Treatment Interval - Change in the Percentage of Cluster of Differentiation 8 and Cluster of Differentiation 28 |
-0.78; -1.6 | — |
| SECONDARY Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 8 and Major Histocompatibility Complex II |
-2.4; 0.5 | — |
| SECONDARY Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 8+ Interferon Gamma |
-4.1; 4.4 | — |
| SECONDARY Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 4+ Interleukin-2 |
-1.7; 4.7 | — |
| SECONDARY Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 8+ Tumor Necrosis Factor |
0.0; 2.3 | — |
| SECONDARY Effects of Cyclosporin A on Respiratory Function - Change in the Percentage of Post Predicted Value of Forced Vital Capacity |
-0.01; 0.07 | — |
| SECONDARY Effects of Cyclosporin A on Respiratory Function - Change in the Percentage of Post Predicted Value of Forced Expiratory Volume in 1 Second |
-0.02; -0.02 | — |
| SECONDARY Effects of Cyclosporin A on Respiratory Function - Change in Exercise Capacity by a Shuttle Walk Distance Measured in Feet |
230; 220 | — |
| SECONDARY Effects of Cyclosporin A on Symptoms - Change in Scores on a Shortness of Breath Scale |
39; 39 | — |
Summary
This is a randomized, double-blinded, placebo-controlled trial of oral Cyclosporine A (CsA) in patients with advanced stage chronic obstructive pulmonary disease. The purpose of the study is to evaluate the safety and effectiveness of CsA as a therapy for the adaptive immune response in advanced stage Chronic Obstructive Pulmonary Disease (COPD).
Subjects between 45 and 80 years of age with a confirmed diagnosis of advanced stage COPD, not responsive to conventional inhaler therapy, who meet all the study requirements, will be enrolled in this study. A total of 30 subjects of either sex will be enrolled in this study.
Eligibility Criteria
Inclusion Criteria
- Age between 45 and 80 years
- A confirmed diagnosis of advanced stage COPD, using current accepted diagnostic criteria, including clinical/laboratory findings, pulmonary function tests, and appropriate history to exclude other disorders that could explain their lung disease. The accepted range of forced expiratory volume at one second will include 25% ≤ forced expiratory volume at one second ≤ 60%
- Subjects agree to maintain a stable medication regimen in the absence of a disease flare
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- carbon dioxide partial pressure 85%
- A willingness to participate in all portions of the protocol, including serial bronchoscopy, requisite surveillances, and ancillary immunologic studies in follow-up visits at this institution
- For woman of childbearing age, a negative pregnancy test, and a willingness to use two methods of contraception, or abstinence
- An ability and willingness to provide written informed consent
Exclusion Criteria
- Three, or more exacerbations of lower respiratory disease in the past year requiring systemic corticosteroids, or one exacerbation requiring hospitalization in the past 6 months
- Intubation for COPD, or other cause of respiratory failure in the past year
- Use of immunosuppressive therapy including oral prednisone > 10mg per day other than aerosolized corticosteroids, anytime within three months prior to participation
- Evidence for an opportunistic infection/colonization of the airways, i.e., non-bacterial
- Evidence for systemic illness including hematologic disorders (defined by an absolute neutrophil count (ANC) 1.5 x normal, serum glutamate oxaloacetate transaminase, or serum glutamate pyruvate transaminase > 1.2 x normal values), or a coagulopathy (INR > 1.4), seizure disorder
- Evidence for renal insufficiency with a calculated creatinine clearance using the Cockcroft and Gault's method of 1.4 mg/dL.
- Evidence of coronary artery disease by history, e.g., angina or history of myocardial infarction within the past 12 months, unless corrected by coronary artery bypass graft within 160 mmHg or diastolic blood pressure >90 mmHg), hyperkalemia (serum potassium > 5.0 meq/dl, and/or elevated serum potassium above the normal range for the subject's age)
- Pregnancy or lactation, or inability to take contraception during and for 6 months following treatment
- Positive HIV, or hepatitis B or C serology, or another active infection
- Current or past history of cancer excluding basal or squamous cell skin cancer
- Undiagnosed pulmonary nodule requiring diagnostic evaluation
- Weight loss > 10% usual body weight over the past 6 months or a BMI 2
- Hypersensitivity to midazolam or narcotics which would not allow bronchoscopy sedation
- Concurrent use of drugs with a known interaction with cyclosporine
Data sourced from ClinicalTrials.gov (NCT00974142). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.